Europe

/Tag:Europe
­

Bionaturis reports a supply contract worth of €4,77 million/year

· The animal health division of Bionaturis Group has signed a license agreement for the supply and distribution of non-prescription products for livestock with minimum annual orders worth of € 4.77 million

· The products subject of the contract are intended to lead to a more rational use of antibiotics in livestock

· The signing of this contract joins the uptrend of significant organic growth that every divisions of the group is performing

Jerez de la Frontera, November 16, 2017.

 

Bionaturis Group has reported that its animal health division has signed a license agreement for the exclusive registration and commercialization of non-prescription products for food production animals (FPAs) with an international client of regional scope. Under the license agreement, Bionaturis will supply the products and technical assistance, while the client will be in charge of importing, distributing and selling them, as well as obtaining the marketing authorization, whose ownership will be shared. The supply agreement has an initial term of three years with automatic renewal of one-year periods and a minimum annual order commitment of €4.77 million euros, once the marketing authorization has been obtained, estimated for the second quarter of 2018.

The products subject of the contract are intended to lead to a more rational use of antibiotics in livestock farms, one of the cornerstones of the One Health concept “one world, one health”, that summarizes an idea that had been known for more than a century; that human health and animal health are interdependent and bound to the health of the ecosystems in which they exist. According to the OIE – World Organization for Animal Health, 60% of known human infectious diseases are zoonotic (domestic or wild animals), as well as 75% of emerging human diseases have animal […]

November 16th, 2017|Blog english|Comments Off on Bionaturis reports a supply contract worth of €4,77 million/year

Bionaturis announces H1-2017 and YTD results

Executive Summary

Reports Revenue YTD of €1.28 million, expecting more than 60% growth for the full year 2017
Reports EBITDA YTD of €355 k, +802 thousand euros compared to the full year 2016
Reports the executions of an exclusive license agreement for the development, registration, manufacturing, and commercialization of BNT005 in Argentina and Paraguay.
Reports the signing of an Evaluation and Licensing agreement with exclusive worldwide license rights (except in Argentina and Paraguay) for the development, registration and commercialization of BNT005 with a top leading company in the sector
Reports ZIP patents granted in USA, EUROPE and JAPAN
Reports reaching an E&O agreement with a global leader for the exclusive development, registration and marketing of a probiotic for oral application, indicated to improve oral health in companion animals
Reports the signing by Biobide of new relevant contracts with three leading companies in the agrochemical and biomedicine sectors, for a cumulative amount worth of USD 1.39 million
Reports BNT005 patent granted in CHINA.

 

Click here to see the official document. (only spanish)

 

October 27th, 2017|Blog english|Comments Off on Bionaturis announces H1-2017 and YTD results

Biobide is involved in two events in Europe.

Biobide, part of Bionaturis Group and CRO of world reference specialized in the zebrafish alternative model, will take part in the following events in September.

*European Teratology Society (Monday 4th – 7th September 2017)

In this annual event will take part Maitane Ipiñazar (Business Development Manager) and Celia Quevedo (Study Director), who will present the poster titled “Toxicity profiling using a battery of assays in zebrafish embryos including teratogenicity, behaviour, cardiotoxicity, ototoxicity and hepatotoxicity”.

The Key sessions for ETS 2017 will include:

· Education Course: Hormones and Brain Development

· Pre-term births

· Safety Assessment of Herbal Drugs in Pregnancy

· Transplacental Exposure to Tumorigenic Agents

· IATA – Integrated Approaches to Testing and Assessment

· Satellite Workshop: Best Practices in interpreting developmental toxicity data

 

To register  you have to enter the official web of the event: https://www.etsoc.com/annual-meeting

 

 

*EUROTOX (Bratislava, 10th -13th September).

Biobide’s delegates from the Business Development area, Maitane Ipiñazar and Ane Altuna, will be the ones attending the event this year, on this occasion as exhibitors with the booth number 32.Moreover, Biobide’s Business Development Manager will present their latest poster the 11th of September (P-03-03-02): “In-silico platform based on bioinformatic and chemoinformatic data to complement zebrafish embryo teratogenicity test.”

The Scientific Programme Committee is preparing an exciting programme with over 30 symposia and workshops that will highlight the novel findings in the field of toxicology. Four Poster Sessions and five Continuing Education Courses will offer a wide range of opportunities to enhance and enrich the professional experience.

To register  you have to enter the official web of the event: http://www.eurotox2017.com/registration/

To arrange a meeting with Biobide in any of these two international events, please write an email to clientes@biobide.es

You can also visit our web: www.biobide.es

August 30th, 2017|Blog english|Comments Off on Biobide is involved in two events in Europe.

Zera®-2 patent of ZIP Solutions also granted in USA

ZIP Solutions –Bionaturis Group- has just been granted with a new patent titled “Protein Body-inducing Polypeptide Sequences” for EEUU, becoming the third patent of the same family, already obtained for Japan and Europe. This patent contributes to a better protection of the Zera Subunit Vaccines 2.0 and Zera DNA Vaccines outstanding applications.

After the granting by The United States Patent and Trademark Office (USPTO), this ZIP Solutions invention is protected in three relevant international markets. The patent family claims the use of second-generation self-assembly fusion sequences, Zera®2, to express and produce recombinant proteins in eukaryotic hosts forming protein bodies. Zera®2 aims to standardize the immune response raised by recombinant vaccines and DNA vaccines plus elimination of the cold-chain by formation of metastable nanostructures.

For further information about this patent, please, click here 

Zera Intein Protein Solutions (ZIP) is all-round bioprocessing, developing and offering highly effective tools for industrial applications of protein-based products such as peptides, recombinant antigens, enzymes, nanobodies, among others. Proprietaries Zera® and Splittera systems – the later subject of an exclusive and worldwide license to a leading multinational company- are optimal solutions to express and purify biological products at industrial scale.

Please, click here to read the Relevant Information (Only in Spanish)

About Bionaturis Group

Bionaturis Group offers premium solutions for human and animal health; it comprises four companies (Bionaturis, Biobide, ZIP Solutions, and BNT Pacific) and two subsidiaries (Biobide USA and BNT China Biosciences) in six different locations around the world. Bionaturis lists on the Spanish stock exchange for SMEs (trading code BNT).

 

May 29th, 2017|Blog english, Hechos Relevantes|Comments Off on Zera®-2 patent of ZIP Solutions also granted in USA

Ojer Pharma and Bionaturis sign a registration and commercialization agreement to market MUPIPET® in Europe

Ojer Pharma and Bionaturis have signed a co-development, registration, and commercialization agreement to market Mupipet® in Europe, the first antibiotic with a bioadhesive and transparent formulation registered in Europe to treat skin bacterial infections in companion animals.

Mupipet® will be registered as a prescription veterinary drug for the topical treatment of skin bacterial infections in companion animals -such as pyoderma- being its main competitive advantage its cutting-edge formulation, developed and patented by the pharmaceutical company Ojer Pharma. Mupipet® is formulated in a transparent bioadhesive film, with acts as a controlled release matrix, ensuring the permanence of the active substance at the site of action and, as a result, a higher efficacy. This system makes unnecessary the use of dressing pads to cover the affected area and reduces product removal accidentally or by scratching and licking, which allows the treatment permanence for at least 12 hours. “The results of field studies already performed demonstrate that Mupipet® has better safety and efficacy profile that other reference products”, Carlos Gonzalez, General Manager at Ojer Pharma, has stated. “The isolation provided by this bioadhesive lipogel formulation reduces the risk of infections and protects the skin against external agents, as well as ensures the permanence of the product in the skin until the infection has been completely removed, with an excellent skin tolerability and non-irritant”, he has added.

“With this agreement, Mupipet® enriches our Premium portfolio for pets, in this case, under the category of prescription drugs. Due to its features, Mupipet® is a unique patent-protected product with outstanding competitive advantages versus other alternatives, and fitting our portfolio requirements. Besides, we expect this strategic agreement consolidates the relationship with Ojer Pharma to start the development of new innovative products. The transparent bioadhesive […]

March 29th, 2017|Blog english|Comments Off on Ojer Pharma and Bionaturis sign a registration and commercialization agreement to market MUPIPET® in Europe

March Newsletter

If you want to know Bionaturis Group, latest news, here you are our March newsletter

IN THIS ISSUE

Zera®-2 patent of ZIP Solutions granted in Europe and Japan

Biobide consolidates its presence in the 56ª SOT Annual Congress –Society of Toxicology – in USA

Bionaturis Group will showcase in BioEurope Spring

Biobide receives the visit of Richard Paules, from NIH-NIEHS

Let’s get to know…

Iñaki Iturria Gallego, 32 years old, born in San Sebastian, degree in Pharmacy by The Basque Country University and Master in Biotechnology. He is currently finishing his PhD in Biosciences by the AZTI Tecnological Center and the same University.

 

-When you were a child, what did you want to be as an adult?
Something related to technology, an IT technician, an engineer…
-What do you like the most about your job?
Facing new challenges and discovering ways to overcome them.
-What are your future challenges?
To continue learning and improving every day.
-Your favourite dish
A large steak.
-A place
Zurriola beach from Sagües, in San Sebastian.
-A film
‘Blade Runner’, by Ridley Scott.
-A historical figure
Louis Pasteur.
-A book
‘Blindness’, by Jose Saramago.
-A song
‘Seven Nation Army’, by The White Stripes.
-What do you usually do in your free time?
Running and spending time with my family and friends.
-You can’t live without…
Being close to the sea.
-How do you imagine the world in 20 years?
A better place, where the scientific advances work together to a bigger social and environmental awareness.

  Iñaki has been working as a R&D Scientist in Biobide (Bionaturis Group) since November, 2016.

Zera®-2 patent of ZIP Solutions granted in Europe and Japan

ZIP Solutions -Bionaturis Group- has been granted with two patents from the same patent family by the European (EPO) and Japanese (JPO) Offices, conferring protection in both territories, two of the most relevant markets worldwide. The patent titled “Protein Body-inducing Polypeptide Sequences” […]

March 14th, 2017|Blog english|Comments Off on March Newsletter

Zera®-2 patent of ZIP Solutions granted in Europe and Japan

ZIP Solutions -Bionaturis Group- has been granted with two patents from the same patent family by the European (EPO) and Japanese (JPO) Offices, conferring protection in both territories, two of the most relevant markets worldwide. The patent titled “Protein Body-inducing Polypeptide Sequences” contributes to a better protection of the Zera Subunit Vaccines 2.0 and Zera DNA Vaccines outstanding applications.

The patent family claims the use of second-generation self-assembly fusion sequences, Zera®2, to express and produce recombinant proteins in eukaryotic hosts forming protein bodies. It is well known that micro particles of protein bodies show high valuable features, such as their capacity to stimulate an immune response in a host when used as non-adjuvant vaccines. Zera®2 aims to standardize the immune response raised by recombinant vaccines and DNA vaccines plus elimination of the cold-chain by formation of metastable nanostructures.

At this regard, Marco Archinti, ZIP IP manager, has pointed out, “Zera® and Zera®2 sequences facilitate to get a high yield of difficult-to-express recombinant antigens, where other traditional approaches fail”. Zera® and Zera®2 tools have already been validated in both in-vitro and in-vivo assays and are included within the portfolio of premium solutions of Bionaturis Group, being a highly efficient and cost-effective way to produce second, third, and fourth generation vaccines.

Zera Intein Protein Solutions (ZIP) is all-round bioprocessing, developing and offering highly effective tools for industrial applications of protein-based products such as peptides, recombinant antigens, enzymes, nanobodies, among others. Proprietaries Zera® and Splittera systems – the later subject of an exclusive and worldwide license to a leading multinational company- are optimal solutions to express and purify biological products at industrial scale.

Please, click here to read the Relevant Information (only in Spanish)

About Bionaturis Group

Bionaturis Group offers premium solutions for human and […]

March 9th, 2017|Blog english|Comments Off on Zera®-2 patent of ZIP Solutions granted in Europe and Japan

Uso de cookies

Este sitio web utiliza cookies para que usted tenga la mejor experiencia de usuario. Si continúa navegando está dando su consentimiento para la aceptación de las mencionadas cookies y la aceptación de nuestra política de cookies, pinche el enlace para mayor información.

CERRAR